We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ekso Bionics Holdings Inc | NASDAQ:EKSO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 0.39% | 1.28 | 1.27 | 1.29 | 1.33 | 1.24 | 1.29 | 22,812 | 19:58:32 |
| | |
Per Share and
Accompanying Warrant |
| |
Total
|
| ||||||
Public Offering Price
|
| | | $ | | | | | $ | | | ||
Underwriting Discount and Commissions
(1)
|
| | | $ | | | | | | $ | | | |
Proceeds to Ekso Bionics Holdings, Inc. (before expenses)
|
| | | $ | | | | | | $ | | | |
|
Lead Book-Running Manager
|
| |
Joint-Book-Running Manager
|
|
|
Cantor
|
| |
SunTrust Robinson Humphrey
|
|
| | |
Page
|
| |||
| | | | S-ii | | | |
| | | | S-iv | | | |
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-5 | | | |
| | | | S-9 | | | |
| | | | S-10 | | | |
| | | | S-11 | | | |
| | | | S-12 | | | |
| | | | S-13 | | | |
| | | | S-15 | | | |
| | | | S-21 | | | |
| | | | S-25 | | | |
| | | | S-30 | | | |
| | | | S-30 | | | |
| | | | S-31 | | | |
| | | | S-32 | | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 16 | | |
| | |
As of March 31, 2019
|
| |||||||||
| | |
Actual
|
| |
As Adjusted
|
| ||||||
| | |
(in thousands, except par value
and per share data) |
| |||||||||
Cash and cash equivalents
|
| | | $ | 9,236 | | | | | $ | | | |
Long-term debt, net
|
| | | $ | 4,426 | | | | | | | | |
Stockholders’ equity: | | | | | | | | | | | | | |
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding
|
| | | | — | | | | | | — | | |
Common stock, $0.001 par value; 141,429 shares authorized; 67,529 shares issued and outstanding, actual, shares issued and outstanding, as adjusted
|
| | | | 68 | | | | | | | | |
Additional paid-in capital
|
| | | | 182,107 | | | | | | | | |
Accumulated other comprehensive income (loss)
|
| | | | 56 | | | | | | | | |
Accumulated deficit
|
| | | | (177,697 ) | | | | | | | | |
Total stockholders’ equity
|
| | | | 4,534 | | | | | | | | |
Total capitalization
|
| | | $ | 8,960 | | | | | $ | | | |
|
|
Public offering price per share and accompanying warrant
(1)
|
| | | | | | | | | $ | | | |
|
Historical net tangible book value per share as of March 31, 2019
|
| | | $ | 0.06 | | | | | | | | |
|
Increase per share attributable to new investors
|
| | | | | | | | | | | | |
|
As adjusted net tangible book value per share as of March 31, 2019, after giving effect to this offering
|
| | | | | | | | | | | | |
|
Dilution per share to new investors purchasing our common stock and warrants in
this offering |
| | | | | | | | | $ | | |
Underwriter
|
| |
Number of Shares
|
| |
Number of
Accompanying Warrants |
| ||||||
Cantor Fitzgerald & Co.
|
| | | | | | | | | | | | |
SunTrust Robinson Humphrey, Inc.
|
| | | | | | | | | | | ||
Total
|
| | | | | | | | | | | | |
|
| | |
Per Share and
Accompanying Warrants |
| |
Total
|
| ||||||
Public offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discounts and commissions
|
| | | $ | | | | | | $ | | | |
Proceeds to us, before expenses
|
| | | $ | | | | | | $ | | | |
| | |
Page
|
| |||
| | | | ii | | | |
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 14 | | | |
| | | | 16 | | | |
Experts | | | | | 16 | | |
| | | | 16 | | | |
| | | | 16 | | |
|
Lead Book-Running Manager
|
| |
Joint-Book-Running Manager
|
| | | |
|
Cantor
|
| |
SunTrust Robinson Humphrey
|
| |
1 Year Ekso Bionics Chart |
1 Month Ekso Bionics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions